Episode 124
Long-term Outcomes in the Chemo-free era for Acute Promyelocytic Leukemia (EHA2024)
Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment.
Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).
Prof Voso highlights contributions of the late prof. Francesco Lo Coco, the significance of the EU-wide HARMONY registry and other collaborative efforts in establishing the optimal treatment regimens for APL. This podcast also provides insights into remaining open issues in the clinical management of APL, including high-risk APL for which the results of the much-anticipated APOLLO trial may provide some answers.
This is part of a series of lectures recorded at the EHA congress in Madrid in June 2024. The podcasts in this series are better consumed in video form because of the accompanying slide content. More lectures will be available in the future. Stay tuned!
For more information about a past or upcoming EHA Congress, visit https://ehaweb.org/congress/
Guest: Prof Maria Teresa Voso
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe